2nd Quarter - Report

TCH GROUP, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

General discussion regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA)

Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Economics/Economic Development ECN

General issues related to foreign direct investment in the United States, including all provisions of S 3274 and HR 5910 "Global Investment in American Jobs Act of 2012"

Foreign entity interest: Sanofi SA, the foreign parent corporation of sanofi-aventis U.S. Inc., as disclosed on its LD-1

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5910 (112th)

Health Issues HCR

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act"; awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR 3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenze pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of Dengue; all provisions of S1002 "Safe Doses Act."

Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2529 (112th), H.R. 3627 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.